PRESS RELEASE published on 06/02/2026 at 07:30, 15 days 7 hours ago Inventiva Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris for a proposed financing transaction. Trading to resume after communication Euronext Paris Trading Halt Clinical Trial Inventiva Metabolic Dysfunction
BRIEF published on 05/26/2026 at 22:05, 21 days 16 hours ago Inventiva Announces its First Quarter 2026 Financial Results Financial Results Treasury Biopharmaceutical Inventiva NATiV3
PRESS RELEASE published on 05/26/2026 at 22:00, 21 days 16 hours ago Inventiva Reports 2026 First Quarter Financial Information¹ Inventiva reports first quarter 2026 financial information, with cash and cash equivalents at €75.0 million and short-term deposits at €121.5 million. Explore company's financial results and upcoming milestones Financial Information Inventiva NATiV3 Cash Equivalents Short-term Deposits
BRIEF published on 05/21/2026 at 22:05, 26 days 16 hours ago Inventiva at the 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva MASH Lanifibranor Jefferies Conference
BRIEF published on 05/21/2026 at 22:05, 26 days 16 hours ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Biopharmaceutical Inventiva Lanifibranor MASH Treatment Jefferies Conference
PRESS RELEASE published on 05/21/2026 at 22:00, 26 days 16 hours ago Inventiva to Present at 2026 Jefferies Global Healthcare Conference Inventiva to present at 2026 Jefferies Global Healthcare Conference in New York City. CEO Andrew Obenshain to speak on June 3, 2026, about MASH therapies Clinical-Stage Biopharmaceutical Inventiva Lanifibranor 2026 Jefferies Conference MASH Therapies
BRIEF published on 05/13/2026 at 08:35, 1 month 4 days ago Inventiva to Present Abstracts at EASL Congress 2026 Biopharmaceutical Research Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 05/13/2026 at 08:35, 1 month 4 days ago Inventiva presents its research on lanifibranor at the EASL Congress 2026 Biopharmaceutical Inventiva MASH Lanifibranor EASL Congress 2026
PRESS RELEASE published on 05/13/2026 at 08:30, 1 month 4 days ago Inventiva to Present Abstracts at the EASL Congress 2026 Inventiva to present two abstracts at EASL Congress 2026 highlighting Lanifibranor's impact on MASH treatment. Lanifibranor, a pan-PPAR agonist, shows promising results in clinical trials Clinical Trials Inventiva Lanifibranor MASH Treatment EASL Congress 2026
BRIEF published on 04/22/2026 at 22:05, 1 month 24 days ago Inventiva Bolsters Executive Team as It Nears Key Phase 3 Data Milestone Phase 3 Trial Lanifibranor Leadership Expansion MASH Treatment Inventiva Biopharmaceutical
Published on 06/17/2026 at 14:00, 44 minutes ago CHAR Tech Reminds Shareholders of June 18 Investor Update Call
Published on 06/17/2026 at 14:00, 44 minutes ago Interpretation of High-Resolution Geophysics at Music Valley HREE Project
Published on 06/17/2026 at 14:00, 44 minutes ago AEONIAN Completes Drilling at Jake Target and Advances District-Scale Copper-Silver Model, Koocanusa Project, BC
Published on 06/17/2026 at 14:35, 9 minutes ago Volkswagen Group's e.solutions selects HCLTech to accelerate innovation for next-generation automotive infotainment and connectivity solutions
Published on 06/17/2026 at 14:35, 9 minutes ago Celebrus Launches Celebrus AI: Bringing Conversational Analytics to Live, Identity-Resolved Compliant Data
Published on 06/17/2026 at 14:10, 34 minutes ago EQS-Adhoc: Sirma Group Holding: Launch of Share Buyback
Published on 06/17/2026 at 14:04, 40 minutes ago Diginex Announces Extension of Long Stop Date for Proposed Acquisition of Resulticks
Published on 06/17/2026 at 08:45, 5 hours 59 minutes ago Air Liquide is awarded its largest-ever contract in Spain to care for 90,000 patients living with respiratory conditions at home
Published on 06/16/2026 at 11:44, 1 day 3 hours ago Guillemot Corporation S.A. | Weekly report share buyback from June 8 to June 12 2026
Published on 06/15/2026 at 23:00, 1 day 15 hours ago BIOPHYTIS ANNOUNCES THE TEMPORARY SUSPENSION OF THE TRADING OF ITS SHARES
Published on 06/15/2026 at 18:57, 1 day 19 hours ago Reporting on share buyback transactions carried out between June 8 and June 11, 2026
Published on 06/15/2026 at 18:32, 1 day 20 hours ago Edenred strengthens its electric charging offering with the acquisition of The Mobility House Solutions
